Article info
PDFPostScript
Letter
Use of cerebrospinal fluid CXCL10 and neopterin as biomarkers in HTLV-1-associated myelopathy/tropical spastic paraparesis treated with steroids
- Correspondence to Dr Yoshihisa Yamano, Department of Rare Diseases Research, Institute of Medical Science, St. Marianna University School of Medicine, Kawasaki 2168512, Japan; yyamano{at}marianna-u.ac.jp
Citation
Use of cerebrospinal fluid CXCL10 and neopterin as biomarkers in HTLV-1-associated myelopathy/tropical spastic paraparesis treated with steroids
Publication history
- Received August 28, 2019
- Revised October 9, 2019
- Accepted October 16, 2019
- First published October 29, 2019.
Online issue publication
November 15, 2022
Article Versions
- Previous version (13 February 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.